ArticlePloS one2020

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.

PLOS ONE StaffPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.